We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Tristel Plc | LSE:TSTL | London | Ordinary Share | GB00B07RVT99 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 10.00 | 2.25% | 455.00 | 19,365 | 16:06:07 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 450.00 | 460.00 | 455.00 | 445.00 | 445.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Med, Dental, Hosp Eq-whsl | 36.01M | 4.46M | 0.0941 | 47.29 | 210.93M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:09:49 | O | 1,500 | 456.40 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 18/4/2024 | 12:42 | ALNC |  IN BRIEF: Tristel CEO Paul Swinney sells GBP230,000 in shares |
| 16/4/2024 | 14:04 | UK RNS | Tristel PLC Director/PDMR Shareholding |
| 15/4/2024 | 17:56 | UK RNS | Tristel PLC Exercise of Share Options and Total Voting Rights |
| 19/3/2024 | 09:25 | UK RNS | Tristel PLC Exercise of Share Options and Total Voting Rights |
| 27/2/2024 | 07:00 | UK RNS | Tristel PLC Exercise of Share Options and Total Voting Rights |
| 26/2/2024 | 09:50 | ALNC | Tristel doubles dividend on revenue and profit boost in first half |
| 26/2/2024 | 07:01 | UK RNS | Tristel PLC Half-year Report |
| 26/2/2024 | 07:00 | UK RNS | Tristel PLC UK and EU regulatory approval update |
| 08/2/2024 | 07:00 | UK RNS | Tristel PLC Exercise of Share Options and Total Voting Rights |
| 01/2/2024 | 07:00 | UK RNS | Tristel PLC Notice of Interim Results |
Tristel (TSTL) Share Charts1 Year Tristel Chart |
|
1 Month Tristel Chart |
Intraday Tristel Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 22/4/2024 | 16:35 | The TRISTEL story | 3,373 |
| 25/3/2024 | 12:43 | Explosive Growth for the foreseeable future | 23 |
| 14/9/2018 | 14:56 | MRSA cleaner | 249 |
| 15/7/2015 | 13:01 | Tristel PLC: Cleaning up the sector | 340 |
| 03/1/2010 | 04:54 | tristel with charts | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:09:50 | 456.40 | 1,500 | 6,846.00 | O |
| 15:07:18 | 456.40 | 2,500 | 11,410.00 | O |
| 15:06:00 | 455.00 | 2,500 | 11,375.00 | O |
| 15:04:10 | 449.00 | 1,060 | 4,759.40 | O |
| 15:03:18 | 450.00 | 95 | 427.50 | O |
| Top Posts |
|---|
Posted at 23/4/2024 09:20 by Tristel Daily Update Tristel Plc is listed in the Med, Dental, Hosp Eq-whsl sector of the London Stock Exchange with ticker TSTL. The last closing price for Tristel was 445p.Tristel currently has 47,400,993 shares in issue. The market capitalisation of Tristel is £210,934,419. Tristel has a price to earnings ratio (PE ratio) of 47.29. This morning TSTL shares opened at 445p |
Posted at 07/4/2024 16:53 by loafofbread Assume you guys know you could pick up Byotrol before it goes private for 1X sales.Buying it for 1p a share £4.3M would boost your share price much more than the cash/share outlay if you apply your current 5 X revenue rating going forward. You have just paid them over £300k to buy back a tiny bit of their IP which shows the value in Byotrol. It would be a shame if your CEO personal friendship with DT got in the way of a great result for Tristel share holders. |
Posted at 11/3/2024 15:47 by z1co The share price rise today is saying a lot of the stock sold after the results has already been bought by buyers. |
Posted at 08/3/2024 15:38 by z1co Yes the seller appeared on the 26/02/2024 hence no further rise in the share price.The seller will eventually finish , they always do and the shares will start climbing upwards again.I'm tempted to buy more but i'm also waiting and watching and will hopefully pounce at the right time. |
Posted at 28/2/2024 15:43 by z1co The analysts are saying that the company will most likely double it's revenue and generate significantly higher profits and free flow cash over the next 5 years.The share price will also achieve new highs , surpassing the previous highs of £7 set in 2021. An excellent company that will also pay progressive dividends , making this a core holding for the long term. |
Posted at 28/2/2024 11:56 by z1co Tristel tipped to double revenue as it targets the North American marketBy John Foster 26th February 2024 Tristel [LON:TSTL] the AIM-listed manufacturer of antibacterial cleaning products published its half-year results today (26th February). The Snailwell-based company specialises in infection prevention. Tristel develops products and solutions to help prevent the spread of harmful microbes, particularly in healthcare settings. Their main focus is on disinfecting medical devices and offers various products, like wipes and solutions, that healthcare professionals can use to disinfect reusable medical devices at the point of use, eliminating the need for sending them to a central sterilization department. The firm also offers products for disinfecting surfaces including large surfaces like floors and walls and the company says that its products are formulated to be effective against a broad spectrum of microorganisms, including bacteria, viruses, and spores. Tristel’s technology utilizes a proprietary chlorine dioxide chemistry that they claim is unique in its effectiveness and safety compared to traditional disinfectants. Back in July 2023 The Armchair Trader noted that Tristel was one on the UK’s top five performing healthcare stocks. In July it was trading at 360p, today Tristel opened at 499.6p climbing to 503.32p on release of its results, up 39.8%. Over one-year the share price is up 45.9% and up 73.6% over five-years. The company saw its revenue grow 20% year-on-year to GBP20.9m in the six-months to the end of December 2023 with overseas sales up 13% to GBP12.7m and earnings up 21% to GBP4.7m Tristel profits and dividends up This led to reported profits before tax of GBP3.4m which were up y-o-y by 44% and the company doubled the interim dividend to 5.25p per share. The company has no debt and cash in the bank of GBP10.8m. Paul Swinney, CEO, who announced his retirement at the end of the year, said in a statement this morning: “I am thrilled that the company continues to thrive and grow, with a pipeline of new product launches planned for the near term […] This six-month period represents the highest sales and profit performance that the company has experienced in its thirty-year history, including during the early COVID era when demand for our products was unprecedented.&rdquo The company experienced strong growth in 2019-20 during the coronavirus pandemic, and as previously reported, was on the verge of entering the North American market, getting the greenlight from US and Canadian regulators to start marketing its products in the region. Sweeney said: “Our North American business strategy focuses on entering each of the key market segments that we dominate in other countries. Ultrasound is our largest segment globally in terms of disinfection procedure events, followed by ENT, cardiology and airway management. Ophthalmology is a very significant global opportunity in terms of disinfection events, but in all countries very few procedures that should be performed with a high-level disinfectant in fact are.” The company is tipped to double its revenue in the next five years, with its North American strategy driving growth, and in the period reported saw the first manufacture and launch of Tristel ULT in the United States, a disinfection product that is used on ultrasound units, which also was cleared by regulators for distribution in Canada. The company already has clearance to sell its Tristel OHP product in Canada, a disinfectant for ophthalmic devices, and Tristel is in the process of submitting Tristel OHP to the US regulators. North American manufacturing plant The company has established a manufacturing facility in the United States, in New Jersey, with Parker Technologies and Swinney noted that during the first ten weeks of activity in North America, Tristel’s revenue and royalty was GBP46,000. He said: “We are very encouraged by this positive start.” Bridgewise rates Tristel as ‘Outperform.&r The simplicity and utility of Tristel’s products make regulatory clearance – often a high hurdle for other biotech companies – a great deal simpler, and the North American healthcare market is a vast and profitable market opportunity that could be transformational for the Cambridgeshire healthcare company. |
Posted at 26/2/2024 17:40 by z1co Good article by the arm chair trader:Tristel tipped to double revenue as it targets the North American market By John Foster 26th February 2024 Tristel [LON:TSTL] the AIM-listed manufacturer of antibacterial cleaning products published its half-year results today (26th February). The Snailwell-based company specialises in infection prevention. Tristel develops products and solutions to help prevent the spread of harmful microbes, particularly in healthcare settings. Their main focus is on disinfecting medical devices and offers various products, like wipes and solutions, that healthcare professionals can use to disinfect reusable medical devices at the point of use, eliminating the need for sending them to a central sterilization department. The firm also offers products for disinfecting surfaces including large surfaces like floors and walls and the company says that its products are formulated to be effective against a broad spectrum of microorganisms, including bacteria, viruses, and spores. Tristel’s technology utilizes a proprietary chlorine dioxide chemistry that they claim is unique in its effectiveness and safety compared to traditional disinfectants. Back in July 2023 The Armchair Trader noted that Tristel was one on the UK’s top five performing healthcare stocks. In July it was trading at 360p, today Tristel opened at 499.6p climbing to 503.32p on release of its results, up 39.8%. Over one-year the share price is up 45.9% and up 73.6% over five-years. The company saw its revenue grow 20% year-on-year to GBP20.9m in the six-months to the end of December 2023 with overseas sales up 13% to GBP12.7m and earnings up 21% to GBP4.7m Tristel profits and dividends up This led to reported profits before tax of GBP3.4m which were up y-o-y by 44% and the company doubled the interim dividend to 5.25p per share. The company has no debt and cash in the bank of GBP10.8m. Paul Swinney, CEO, who announced his retirement at the end of the year, said in a statement this morning: “I am thrilled that the company continues to thrive and grow, with a pipeline of new product launches planned for the near term […] This six-month period represents the highest sales and profit performance that the company has experienced in its thirty-year history, including during the early COVID era when demand for our products was unprecedented.&rdquo The company experienced strong growth in 2019-20 during the coronavirus pandemic, and as previously reported, was on the verge of entering the North American market, getting the greenlight from US and Canadian regulators to start marketing its products in the region. Sweeney said: “Our North American business strategy focuses on entering each of the key market segments that we dominate in other countries. Ultrasound is our largest segment globally in terms of disinfection procedure events, followed by ENT, cardiology and airway management. Ophthalmology is a very significant global opportunity in terms of disinfection events, but in all countries very few procedures that should be performed with a high-level disinfectant in fact are.” The company is tipped to double its revenue in the next five years, with its North American strategy driving growth, and in the period reported saw the first manufacture and launch of Tristel ULT in the United States, a disinfection product that is used on ultrasound units, which also was cleared by regulators for distribution in Canada. The company already has clearance to sell its Tristel OHP product in Canada, a disinfectant for ophthalmic devices, and Tristel is in the process of submitting Tristel OHP to the US regulators. North American manufacturing plant The company has established a manufacturing facility in the United States, in New Jersey, with Parker Technologies and Swinney noted that during the first ten weeks of activity in North America, Tristel’s revenue and royalty was GBP46,000. He said: “We are very encouraged by this positive start.” Bridgewise rates Tristel as ‘Outperform.&r The simplicity and utility of Tristel’s products make regulatory clearance – often a high hurdle for other biotech companies – a great deal simpler, and the North American healthcare market is a vast and profitable market opportunity that could be transformational for the Cambridgeshire healthcare company. |
Posted at 26/2/2024 16:05 by z1co The management today have increased the interim dividend by 100% to 5.24p , this is a clear sign that they are very confident that the company will keep growing it's revenue , PBT , EPS and also be very cash generative.Very rare that a company increases it's dividend this much unless they know that their business will trade very strongly and ahead of expectations for the foreseeable future. In the past companies that have significantly increased their dividends , their share price has also performed very strongly. |
Posted at 26/2/2024 15:10 by 74tom Presentation certainly didn't set the world on fire, it felt a bit as though the CFO was hung out to dry by the CEO, who sat next to her but only answered one question (and the answer was by far the most comprehensive & confident of the meeting). Unsure why the outgoing CEO felt the need to be a bystander, especially after such positive results.Valuation looks challenging to me, (even assuming for a full year beat and 14p EPS, they are on 33x FY24 P/E) especially if they want to be treated as a growth company but insist on paying out a material proportion of their EPS as a dividend. Wouldn't shareholders prefer them to invest in their R&D resource so they can get products to market faster? Nanosonics also reported today on the ASX , missed expectations & shares fell 15% to multi year lows. Their revenues are double TSTL, but due to them spending ~£16m PA on R&D their reported PBT fell to below TSTL. Market cap down to £410m with £60m cash, so on an EV/Sales basis they are now around 20% cheaper than TSTL vs level pegging on Friday. Quite a divergence, which is understandable based on today's results alone, but seems to underestimate their installed base on 30k machines in the US. Either way, a quality company & long term success story, but based on today's call I'd be concerned that the outgoing CEO will be difficult to replace and hence the 34x rating offers next to no margin of safety. |
Posted at 26/2/2024 08:06 by paulisi Decent results. Expect further growth on a high margin once US sales kick in.Nice upward movement in share price this morning. |
Posted at 23/2/2021 17:25 by james188 There are many possible reasons for the recent TSTL share price activity (including IG recently deciding to withdraw from small cap stocks), but it does not matter much to medium and long term holders.Over time in recent years, the share price trajectory has been excellent and there is an obvious roll out strategy which is by no means solely reliant on North America. The company has barely got started in South-East Asia, has no presence in South America and is now projecting initial sales in India next month. The fact that the company remains debt free and relatively conservative are significant plusses for me. The end game may well be TSTL being acquired by a much larger fish, but why not enjoy the ride? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
